Effects of Nicotinamide Riboside on Fat Metabolism and Energy Use

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation &Amp;Amp;Amp;Amp; Metabolic Rate

This study is testing whether taking nicotinamide riboside along with a low-carb diet can help adults with overweight or obesity burn fat and use energy better while they sleep.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
• Locations: 1 site (Bethesda, Maryland)
• Trial ID: NCT06044935 on ClinicalTrials.gov

What this trial studies

This study investigates how nicotinamide riboside (NR) supplementation and a low-carbohydrate ketogenic diet influence fat oxidation and energy expenditure during sleep in adults with overweight or obesity. It is a randomized, double-blind, placebo-controlled crossover design, where participants will undergo a screening visit followed by clinic stays to assess their metabolic responses. The study aims to determine the effects of NR on metabolic rates compared to a baseline high-carbohydrate diet, focusing on both men and women, including those with maturity-onset diabetes of the young type 2 (MODY2). Exploratory measurements will also be taken to better understand the metabolic changes associated with these interventions.

Who should consider this trial

Good fit: Ideal candidates include healthy men aged 18-65 and pre-menopausal women aged 18-50 with a body mass index of 25 or more, as well as adults with MODY2.

Not a fit: Patients who are not overweight or obese, or those taking medications that may interfere with the study's outcomes, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide new insights into dietary and supplemental strategies for improving metabolic health in individuals with overweight or obesity.

How similar studies have performed: Other studies have shown promising results with similar dietary interventions and supplementation, suggesting potential for success in this approach.

Eligibility criteria

* INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Meet one of the following:

   1. Adult males aged 18-65 years
   2. Pre-menopausal adult females aged 18-50 years
   3. Adult males aged 18-65 years with diagnosed maturity-onset diabetes of the young type 2 (MODY2) or pre-menopausal adult females aged 18-50 years with diagnosed MODY2
2. Weight stable (\< +/- 5 % body weight change over past 6 months) as determined by volunteer report
3. Body mass index (BMI) \>= 25 kg/m\^2 (of \>=18.5 kg/m\^2 for patients with MODY2)
4. Able to cycle at a moderate rate and intensity with a HR equal to or greater than 0.3x(220-age-HRrest)+HRrest but not exceeding 0.4x(220-age-HRrest)+HRrest with no signs of arrhythmia

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Taking prescription medications or other drugs or supplements that may influence energy metabolism or nutrient digestion or absorption (including, but not limited to, diet/weight-loss medication or other medications at the discretion of the PI and/or study team)
2. Indicators of liver disease; combination of both albumin \< 2.8 mg/mL and bilirubin \> 3 mg/mL
3. Individuals with significant medical comorbidities (e.g., non-MODY2 diabetes, NYHA Class \>II heart failure, or CKD Stage II or worse, or American Society of Anesthesiologists Physical Status Class 3 or above)
4. Individuals taking prescription medications to treat hypertension in participants without MODY2
5. Participating in a regular exercise program (\> 2h/week of vigorous activity) as determined by volunteer report
6. Positive pregnancy test (only for people who can get pregnant)
7. Hematocrit \< 40% (men only)
8. Hematocrit \<37% (women only)
9. Caffeine consumption \> 300 mg/day as determined by volunteer report
10. Alcohol consumption \> 3 drinks per day for men or \> 2 drinks per day for women as determined by volunteer report
11. Regular use of tobacco (smoking or chewing), e-cigarettes (a.k.a. vapes), nicotine patches, or illicit drugs over past 6 months as determined by volunteer report. Subjects may also be excluded based on a urine drug test.
12. Psychological conditions as determined by volunteer report such as (but not limited to) eating disorders, depression, bipolar disorders, that would be incompatible with safe and successful participation in this study, as determined by investigators
13. Volunteers with strict dietary concerns (e.g. vegetarian or kosher diet, food allergies) or a reported dislike of a significant fraction of the study foods
14. Unwilling or unable to comply with or perform all study procedures (e.g. cycling or activities of daily living), or unavailability for the duration of the study, as determined by participant or investigator discretion
15. Unwilling or unable to adhere to Lifestyle Considerations throughout study duration, as determined by participant or investigator discretion
16. Volunteers unwilling or unable to give informed consent
17. Participants with a measured Resting Energy Expenditure (REE) more than 30% above or below the predicted REE based on Mifflin St Jeor equation

Where this trial is running

Bethesda, Maryland

• National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)

Study contacts

• Principal investigator: Stephanie T Chung, M.D. — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Study coordinator: Nan Zhai, C.R.N.P.

Conditions Overweight; Obesity; Ketogenic Diet; Sleep; Energy Expenditure; Supplement; Calories